Shamsollahi H, Younesian S, Nikfarjam A, Nasiri Z, Yunesian M
Heliyon. 2025; 11(4):e42670.
PMID: 40051856
PMC: 11883369.
DOI: 10.1016/j.heliyon.2025.e42670.
Solanki G, Cleary S, Little F
PLoS One. 2025; 20(1):e0317686.
PMID: 39854537
PMC: 11760578.
DOI: 10.1371/journal.pone.0317686.
Piccoli B, Y Castro T, Tessele L, Casarin B, Seerig A, Vieira A
Sci Rep. 2024; 14(1):16831.
PMID: 39039137
PMC: 11263389.
DOI: 10.1038/s41598-024-67828-7.
Kassanjee R, Davies M, Heekes A, Mahomed H, Hawkridge A, Morden E
Vaccines (Basel). 2024; 12(6).
PMID: 38932357
PMC: 11209070.
DOI: 10.3390/vaccines12060628.
de Rioja V, Basile L, Perramon-Malavez A, Martinez-Solanas E, Lopez D, Medina Maestro S
Vaccines (Basel). 2024; 12(5).
PMID: 38793717
PMC: 11125683.
DOI: 10.3390/vaccines12050466.
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.
Iketani S, Ho D
Cell Chem Biol. 2024; 31(4):632-657.
PMID: 38640902
PMC: 11084874.
DOI: 10.1016/j.chembiol.2024.03.008.
All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer.
Li W, Li Y, Li J, Meng J, Jiang Z, Yang C
Adv Sci (Weinh). 2024; 11(22):e2309770.
PMID: 38528670
PMC: 11165559.
DOI: 10.1002/advs.202309770.
A review of the clinical characteristics and management of immunosuppressed patients living with HIV or solid organ transplants infected with SARS-CoV-2 omicron variants.
Song Y, Lou L, Zhang K
Front Public Health. 2024; 12:1327093.
PMID: 38454994
PMC: 10917969.
DOI: 10.3389/fpubh.2024.1327093.
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
Gayed J, Diya O, Lowry F, Xu X, Bangad V, Mensa F
Vaccines (Basel). 2024; 12(2).
PMID: 38400102
PMC: 10893482.
DOI: 10.3390/vaccines12020118.
Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada.
Wu S, Li Y, Baral S, Mishra S, Koh M, Golding H
PLoS One. 2024; 19(2):e0299304.
PMID: 38394091
PMC: 10889649.
DOI: 10.1371/journal.pone.0299304.
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination.
Zhao X, Qiu T, Huang X, Mao Q, Wang Y, Qiao R
Cell Discov. 2024; 10(1):14.
PMID: 38320990
PMC: 10847457.
DOI: 10.1038/s41421-024-00648-1.
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2.
Bruch E, Zhu S, Szymkowicz L, Blake T, Kiss T, James D
Sci Rep. 2024; 14(1):2038.
PMID: 38263191
PMC: 10805794.
DOI: 10.1038/s41598-024-52499-1.
In Reply to "Using Immunoglobulin G Spike Antibodies as a Surrogate Marker for Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Additional Considerations".
Hsu C, Weiner D, Manley H, Johnson D, Lacson Jr E
Kidney Med. 2024; 6(1):100781.
PMID: 38259727
PMC: 10801208.
DOI: 10.1016/j.xkme.2023.100781.
Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients.
Affeldt P, Brensing K, Heger E, Wirtz M, Steger G, Koehler F
Clin Kidney J. 2023; 16(12):2757-2759.
PMID: 38046037
PMC: 10690076.
DOI: 10.1093/ckj/sfad230.
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
Usdan L, Patel S, Rodriguez H, Xu X, Lee D, Finn D
Clin Infect Dis. 2023; 78(5):1194-1203.
PMID: 38016021
PMC: 11093671.
DOI: 10.1093/cid/ciad718.
Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals.
Park J, Jeon J, Um J, Choi Y, Kim M, Lee K
Infect Chemother. 2023; 56(1):25-36.
PMID: 38014726
PMC: 10990888.
DOI: 10.3947/ic.2023.0057.
Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy.
Rudolph A, Khan F, Shah A, Singh T, Wiemken T, Puzniak L
J Infect Dis. 2023; 229(3):648-659.
PMID: 37925630
PMC: 10938215.
DOI: 10.1093/infdis/jiad474.
Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies.
Zendt M, Bustos Carrillo F, Kelly S, Saturday T, Degrange M, Ginigeme A
Sci Adv. 2023; 9(41):eadh3150.
PMID: 37824621
PMC: 10569702.
DOI: 10.1126/sciadv.adh3150.
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.
Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden L
Nat Med. 2023; 29(9):2334-2346.
PMID: 37640860
PMC: 10504073.
DOI: 10.1038/s41591-023-02503-4.
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE).
Ison M, Weinstein D, Dobryanska M, Holmes A, Phelan A, Li Y
Open Forum Infect Dis. 2023; 10(7):ofad314.
PMID: 37496612
PMC: 10368201.
DOI: 10.1093/ofid/ofad314.
